Tech Company Financing Transactions
Juventas Therapeutics Funding Round
Juventas Therapeutics closed a $12 million investment round on 2/10/2012. Investors included Early Stage Partners and private investors.
Transaction Overview
Company Name
Announced On
2/10/2012
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will be used to finance two Phase II clinical trials of its lead compound, JVS-100, which recruits stem cells to the site of damaged tissue.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3615 Superior Ave. 4403B
Cleveland, OH 44114
USA
Cleveland, OH 44114
USA
Phone
Website
Email Address
Overview
Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life--threatening diseases. The company's lead product, Stromal--cell Derived Factor 1 (SDF--1), has been shown to protect and repair tissue following organ--damage in a broad range of pre--clinical disease models.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
Chief Medical Officer
Matthew Pollman
VP - Operations
Michael Fitzgerald
VP - Product Management
Joseph Pastore
Browse more venture capital transactions:
Prev: 2/10/2012: Checkpoint Surgical venture capital transaction
Next: 2/10/2012: Genologics Life Sciences Software venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs